Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails ...

T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and/or bispecific antibody (BsAb) has been established and become a promising treatment strategy for relapsed/refractory B-cell ...

Researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific ...

A version of this article was originally published on CancerNetwork. This version has been lightly edited. The FDA has granted accelerated approval to talquetamab-tgvs (Talvey) for patients with ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Reduced-intensity dosing of talquetamab may improve tolerability without compromising efficacy among ...

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects. Now new research by Fox Chase Cancer Center physicians shows ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to talquetamab-tgvs for treatment of certain patients with relapsed or ...

New York, NY (September 1, 2022) — Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line ...